Today
Earnings
Show Hide Related Items >> <<
06/30/22 Genmab to submit FDA application for epcoritamab in B-cell lymphoma 06/27/22 AbbVie: CHMP recommends approval of Rinvoq in nr-axSpA in adults 06/21/22 AbbVie submits sNDA to FDA for atogepant 06/17/22 AbbVie: FDA approves SKYRIZI to treat Crohn's disease 05/23/22 SVB Securities AbbVie initiated with an Underperform at SVB Leerink 05/13/22 Piper Sandler Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler 05/06/22 Daiwa AbbVie downgraded to Neutral from Outperform at Daiwa 05/03/22 Morgan Stanley Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure 16:24 Today AbbVie sees Q2 $3.24-$3.28, consensus $3.43 04/29/22 AbbVie sees FY22 revenue $59.4B, consensus $60.22B 04/29/22 AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50 04/29/22 AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports 05/23/22 What You Missed On Wall Street On Monday 05/23/22 What You Missed On Wall Street This Morning 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/10/22 What You Missed On Wall Street On Tuesday 04/29/22 Unusually active option classes on open April 29th 02/24/22 AbbVie put volume heavy and directionally bearish 01/24/22 AbbVie put volume heavy and directionally bearish
Earnings
Show Hide Related Items >> <<
06/30/22 Genmab to submit FDA application for epcoritamab in B-cell lymphoma 06/27/22 AbbVie: CHMP recommends approval of Rinvoq in nr-axSpA in adults 06/21/22 AbbVie submits sNDA to FDA for atogepant 06/17/22 AbbVie: FDA approves SKYRIZI to treat Crohn's disease 05/23/22 SVB Securities AbbVie initiated with an Underperform at SVB Leerink 05/13/22 Piper Sandler Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler 05/06/22 Daiwa AbbVie downgraded to Neutral from Outperform at Daiwa 05/03/22 Morgan Stanley Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure 04/29/22 AbbVie sees FY22 revenue $59.4B, consensus $60.22B 04/29/22 AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50 04/29/22 AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20 04/29/22 AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports 05/23/22 What You Missed On Wall Street On Monday 05/23/22 What You Missed On Wall Street This Morning 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/10/22 What You Missed On Wall Street On Tuesday 04/29/22 Unusually active option classes on open April 29th 02/24/22 AbbVie put volume heavy and directionally bearish 01/24/22 AbbVie put volume heavy and directionally bearish
Hot Stocks
Show Hide Related Items >> <<
10:36 Today Pfizer announces non-exclusive patent license agreement with Touchlight 07/05/22 CureVac files patent infringement suit in Germany against BioNTech 06/30/22 Pfizer submits NDA to FDA for PAXLOVID 06/29/22 Pfizer/BioNTech enter new $3.2B deal with U.S. government on COVID vaccines 06:26 Today Evercore ISI Enanta upgraded to Outperform at Evercore ISI ahead of COVID anti-viral data 07/01/22 RBC Capital Enanta price target raised to $67 from $64 at RBC Capital 06/29/22 Evercore ISI Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data 06/22/22 Piper Sandler Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open 06/28/22 FDA panel recommends omicron update for COVID vaccine boosters, CNBC says 06/23/22 Moderna vaccine for kids gets backing of CDC advisers, WSJ reports 06/12/22 Review says Pfizer vaccine works safely in young children, WSJ reports 06/02/22 Pfizer ask FDA to authorize three doses of vaccine for kids under 5, WSJ report 06/30/22 What You Missed On Wall Street On Thursday 06/30/22 What You Missed On Wall Street This Morning 06/30/22 Fly Intel: Pre-market Movers 06/29/22 What You Missed On Wall Street On Wednesday 06/30/22 Early notable gainers among liquid option names on June 30th 05/20/22 Early notable gainers among liquid option names on May 20th 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th
Hot Stocks
Show Hide Related Items >> <<
07/05/22 CureVac files patent infringement suit in Germany against BioNTech 06/30/22 Pfizer submits NDA to FDA for PAXLOVID 06/29/22 Pfizer/BioNTech enter new $3.2B deal with U.S. government on COVID vaccines 06/28/22 Pfizer and Roivant Sciences unveil Priovant Therapeutics 06:26 Today Evercore ISI Enanta upgraded to Outperform at Evercore ISI ahead of COVID anti-viral data 07/01/22 RBC Capital Enanta price target raised to $67 from $64 at RBC Capital 06/29/22 Evercore ISI Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data 06/22/22 Piper Sandler Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open 06/28/22 FDA panel recommends omicron update for COVID vaccine boosters, CNBC says 06/23/22 Moderna vaccine for kids gets backing of CDC advisers, WSJ reports 06/12/22 Review says Pfizer vaccine works safely in young children, WSJ reports 06/02/22 Pfizer ask FDA to authorize three doses of vaccine for kids under 5, WSJ report 06/30/22 What You Missed On Wall Street On Thursday 06/30/22 What You Missed On Wall Street This Morning 06/30/22 Fly Intel: Pre-market Movers 06/29/22 What You Missed On Wall Street On Wednesday 06/30/22 Early notable gainers among liquid option names on June 30th 05/20/22 Early notable gainers among liquid option names on May 20th 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th
Upgrade
Evercore ISI analyst…
Evercore ISI analyst Liisa Bayko upgraded Enanta (ENTA) to Outperform from In Line with a $62 price target, telling investors that she believes the Phase 1 first-in-human data for its COVID anti-viral data due in July will show that its once-daily COVID protease inhibitor, EDP-235, doesn't require ritonavir to reach exposures needed for a strong anti-viral effect like Pfizer's (PFE) Paxlovid does. The anti-viral "could be best in class and partnerable," added Bayko, who is assuming a 20% probability of success for EDP-235 being commercialized by a pharma partner.
Show Hide Related Items >> <<
07/05/22 CureVac files patent infringement suit in Germany against BioNTech 06/30/22 Pfizer submits NDA to FDA for PAXLOVID 06/29/22 Pfizer/BioNTech enter new $3.2B deal with U.S. government on COVID vaccines 06/28/22 Pfizer and Roivant Sciences unveil Priovant Therapeutics 06/21/22 Enanta files patent infringement lawsuit against Pfizer 05/18/22 Enanta falls 13% after announcing EDP-938 did not meet primary endpoint 05/18/22 Enanta says EDP-938 did not meet primary endpoint in RSVP study 05/18/22 Enanta reports topline data from RSVP study of EDP-938 06:15 Today Evercore ISI Enanta upgraded to Outperform from In Line at Evercore ISI 07/01/22 RBC Capital Enanta price target raised to $67 from $64 at RBC Capital 06/22/22 Piper Sandler Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler 05/31/22 Evercore ISI Enanta upgraded to In Line from Underperform at Evercore ISI 06/29/22 Evercore ISI Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data 06/13/22 Morgan Stanley Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open 05/09/22 Enanta reports Q2 EPS ($1.63), consensus ($1.43) 02/08/22 Enanta reports Q1 EPS ($1.48), consensus ($1.08) 02/08/22 Enanta reports Q1 EPS ($1.48), Bloomberg says 06/28/22 FDA panel recommends omicron update for COVID vaccine boosters, CNBC says 06/23/22 Moderna vaccine for kids gets backing of CDC advisers, WSJ reports 06/12/22 Review says Pfizer vaccine works safely in young children, WSJ reports 06/02/22 Pfizer ask FDA to authorize three doses of vaccine for kids under 5, WSJ report 06/30/22 What You Missed On Wall Street On Thursday 06/30/22 What You Missed On Wall Street This Morning 06/30/22 Fly Intel: Pre-market Movers 06/29/22 What You Missed On Wall Street On Wednesday 05/18/22 Fly Intel: After-Hours Movers 03/28/22 Fly Insider: GameStop, Agilent among this week's notable insider trades 06/30/22 Early notable gainers among liquid option names on June 30th 05/20/22 Early notable gainers among liquid option names on May 20th 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th
Yesterday
Recommendations
Stifel analyst Craig…
Stifel analyst Craig Jones noted that Bloomberg reported that 1Life Healthcare (ONEM) is considering potential takeover offers after receiving interest from CVS Health (CVS) and others, though the report said CVS is no longer interested and no other companies were mentioned by name. If CVS were interested, it is "logical to assume" Walgreens (WBA) would be as well, according to Jones, who adds that the payor group - including UnitedHealth (UNH), Humana (HUM), Cigna (CI) and Centene (CNC) - would be among other "logical acquirers." Jones keeps a Buy rating and $12 price target on 1Life Healthcare shares, which closed up nearly 25% at $10.34.
Show Hide Related Items >> <<
WBA Walgreens Boots Alliance 06/28/22 NeuroMetrix appoints Fluegel to board of directors 06/28/22 Walgreens Boots Alliance ends strategic review, to keep ownership of Boots unit 06/28/22 Walgreens Boots Alliance to retain ownership of Boots business, ends review 06/26/22 Fly Intel: Top five weekend stock stories $505.29 / -11.83 (-2.29%)
06/17/22 UnitedHealth subsidiary to acquire EMIS Group in deal valued at GBP 1.24B 06/10/22 LHC Group, UnitedHealth receive second request for information from FTC 06/08/22 UnitedHealth announces quarterly dividend of $1.65 per share $10.32 / +2.065 (+25.02%)
07/05/22 1Life Healthcare up 14% to $9.46 after Bloomberg report of takeover interest 07/05/22 1Life Healthcare trading resumes 07/05/22 1Life Healthcare trading halted, volatility trading pause 02/24/22 1Life Healthcare trading resumes 06/13/22 Humana launches CenterWell Pharmacy, CenterWell Specialty Pharmacy 06/09/22 Humana's onehome announces expansion to Virginia 05/13/22 Starboard takes stake in Humana, exits System1 06/30/22 CVS Health exec sells $13.2M in common stock 06/07/22 FTC announces inquiry into pharmacy benefit managers 05/09/22 Aris Water Solutions reaches water management pact with Chevron 05/04/22 CVS Health reports 98% core client retention for 2023 selling season 06/17/22 Centene to lower real estate footprint, increase share repurchase program by $3B 06/14/22 New Mexico AG announces $13.7M settlement with Centene over PBM claims 05/10/22 Centene, Behavioral Health Center of Excellence enter partnership 05/05/22 Centene divests two pharmacy businesses for total proceeds of $2.8B 06/16/22 Cigna announces $3.5B accelerated stock repurchase agreements 05/02/22 Bioventus agrees to nationwide contract with Cigna for DUROLANE, GELSYN-3 03/08/22 Kala Pharmaceuticals announces EYSUVIS now covered by UnitedHealthcare, Cigna $10.32 / +2.065 (+25.02%)
06/16/22 Deutsche Bank 1Life Healthcare market cap now below last private raise, says Deutsche Bank 05/26/22 Stifel 1Life Healthcare initiated with a Buy at Stifel 05/24/22 Piper Sandler 1Life Healthcare price target lowered to $15 from $20 at Piper Sandler 05/06/22 Deutsche Bank 1Life Healthcare price target lowered to $11 from $16 at Deutsche Bank 06/16/22 Loop Capital Loop Capital starts CVS Health at Buy citing position to capitalize on Medicare 06/16/22 Loop Capital CVS Health initiated with a Buy at Loop Capital 06/03/22 Morgan Stanley CVS deal a 'game-changer' for Amwell's Converge, says Morgan Stanley 05/26/22 Bernstein CVS Health downgraded to Market Perform from Outperform at Bernstein WBA Walgreens Boots Alliance 07/05/22 RBC Capital Walgreens Boots Alliance price target lowered to $42 from $46 at RBC Capital 07/01/22 Morgan Stanley Walgreens consensus needs to come down by more than 11%, says Morgan Stanley 07/01/22 Credit Suisse Walgreens Boots Alliance price target lowered to $43 from $52 at Credit Suisse 07/01/22 Deutsche Bank Walgreens Boots Alliance price target lowered to $44 from $46 at Deutsche Bank $505.29 / -11.83 (-2.29%)
06/16/22 Loop Capital Loop starts UnitedHealth at Buy, sees company having 'major' advantages 06/16/22 Loop Capital UnitedHealth initiated with a Buy at Loop Capital 06/01/22 Citi Change Healthcare price target raised to $27.75 from $25.75 at Citi 05/26/22 Bernstein UnitedHealth downgraded to Market Perform at Bernstein on valuation 06/16/22 Loop Capital Loop starts Humana at Buy on brand and growing portfolio 06/16/22 Loop Capital Humana initiated with a Buy at Loop Capital 05/26/22 Bernstein Humana resumed with a Market Perform at Bernstein 04/28/22 Wells Fargo Humana price target raised to $512 from $491 at Wells Fargo 06/22/22 Morgan Stanley Anthem downgraded to Equal Weight from Overweight at Morgan Stanley 06/22/22 Morgan Stanley Cigna upgraded to Overweight from Equal Weight at Morgan Stanley 06/16/22 Loop Capital Loop starts Cigna at Hold, says major reclassifications now 'behind us' 06/16/22 Loop Capital Cigna initiated with a Hold at Loop Capital 06/22/22 Deutsche Bank Centene price target raised to $91 from $88 at Deutsche Bank 06/21/22 Credit Suisse Centene upgraded to Outperform from Neutral at Credit Suisse 06/16/22 Loop Capital Loop Capital starts Centene at Buy on greater profitability, shareholder returns 06/16/22 Loop Capital Centene initiated with a Buy at Loop Capital WBA Walgreens Boots Alliance 06/30/22 Walgreens Boots Alliance backs FY22 EPS outlook of low single digit growth 06/30/22 Walgreens Boots Alliance reports Q3 adjusted EPS 96c, consensus 92c 06/29/22 Notable companies reporting before tomorrow's open $505.29 / -11.83 (-2.29%)
04/14/22 UnitedHealth raises FY22 adjusted EPS view to $21.20-$21.70 from $21.10-$21.60 04/14/22 UnitedHealth reports Q1 adjusted EPS $5.49, consensus $5.38 04/13/22 Notable companies reporting before tomorrow's open $10.32 / +2.065 (+25.02%)
05/04/22 1Life Healthcare sees FY22 revenue $1.055B-$1.095B, consensus $1.07B 05/04/22 1Life Healthcare sees Q2 revenue $255M-$270M, consensus $263.36M 05/04/22 1Life Healthcare reports Q1 EPS (47c), consensus (49c) 02/23/22 1Life Healthcare sees FY22 revenue $1.05B-$1.09B, consensus $1.07B 06/01/22 Humana backs FY22 adjusted EPS view of about $24.50, consensus $24.63 04/27/22 Humana raises FY22 adjusted EPS view to 'approximately $24.50' 04/27/22 Humana reports Q1 adjusted EPS $8.04, consensus $6.78 02/02/22 Humana sees FY22 adjusted EPS at least $24.00, consensus $23.85 06/09/22 CVS Health reaffirms FY22 adjusted EPS view $8.20-$8.40, consensus $8.36 05/04/22 CVS Health raises FY22 Health Care benefits revenue view to $89.3B-$90.8B 05/04/22 CVS Health raises FY22 revenue view to $305B-$310B from $304B-$309B 05/04/22 CVS Health raises FY22 adjusted EPS view to $8.20-$8.40 from $8.10-$8.30 06/17/22 Centene raises FY22 adjusted EPS view to $5.55-$5.70 from $5.40-$5.55 04/26/22 Centene raises FY22 adjusted EPS view to $5.40-$5.55 from $5.30-$5.50 04/26/22 Centene reports Q1 adjusted EPS $1.83, consensus $1.68 04/25/22 Notable companies reporting before tomorrow's open 06/03/22 Cigna affirms FY22 EPS 'at least' $22.60 and revenue of 'at least $177B' 05/06/22 Cigna raises FY22 adjusted EPS view to at least $22.60 from at least $22.40 05/06/22 Cigna reports Q1 adjusted EPS $6.01, consensus $5.18 05/05/22 Notable companies reporting before tomorrow's open WBA Walgreens Boots Alliance 06/26/22 Reliance in talks to raise up to $8B for Boots, Mint reports 06/24/22 Walgreens settles class-action lawsuit for $105M, Reuters reports 06/22/22 Four banks lined up to fund Apollo-Reliance bid for Boots, Sky News says 05/26/22 Issa, TDR said to consider dropping out of bidding for Boots, Bloomberg reports $505.29 / -11.83 (-2.29%)
05/20/22 UnitedHealth focuses on telehealth to reduce costs, WSJ reports 04/04/22 Change Healthcare in talks to sell ClaimsXten business, Bloomberg says 03/24/22 UnitedHealth's Optum bought Refresh Mental Health from PE owner, Axios reports 02/24/22 UnitedHealth plans to challenge DOJ's lawsuit, Reuters reports $10.32 / +2.065 (+25.02%)
07/05/22 1Life Healthcare weighs options after drawing takeover interest, Bloomberg says 07/05/22 1Life Healthcare weighs options after drawing takeover interest, Bloomberg says 03/08/22 Lawmakers considering extending telehealth policies, STATNews reports 04/21/22 Humana in talks to sell arm of its Kindred at Home to CD&R, Bloomberg reports 01/11/22 Insurers to cover rapid Covid-19 tests under White House plan, WSJ reports 06/27/22 CVS, Walmart rationing Plan B pills amid demand surge, WSJ reports 05/25/22 CVS to stop filling controlled substance prescriptions for Cerebral, WSJ reports 02/04/22 California signs secret Medicaid deal with Kaiser Permanente, KHN reports 01/26/22 Centene attracted acquisition interest from Cigna recently, Bloomberg says 01/26/22 Centene draws takeover interest from Cigna in recent months, Bloomberg says WBA Walgreens Boots Alliance 06/30/22 What You Missed On Wall Street On Thursday 06/30/22 What You Missed On Wall Street This Morning 06/30/22 Fly Intel: Pre-market Movers 06/28/22 What You Missed On Wall Street On Tuesday $505.29 / -11.83 (-2.29%)
05/27/22 What You Missed On Wall Street On Friday 05/27/22 What You Missed On Wall Street This Morning 05/27/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations $10.32 / +2.065 (+25.02%)
07/05/22 What You Missed On Wall Street On Tuesday 05/04/22 Fly Intel: After-Hours Movers 02/23/22 Fly Intel: After-Hours Movers 06/01/22 What You Missed On Wall Street On Wednesday 06/01/22 What You Missed On Wall Street This Morning 04/13/22 What You Missed On Wall Street On Wednesday 06/17/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/22 What You Missed On Wall Street On Thursday 06/09/22 What You Missed On Wall Street This Morning 06/07/22 What You Missed On Wall Street On Tuesday 06/17/22 What You Missed On Wall Street On Friday 06/17/22 What You Missed On Wall Street This Morning 06/17/22 Fly Intel: Pre-market Movers 06/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/16/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations WBA Walgreens Boots Alliance 06/17/22 Unusually active option classes on open June 17th 05/18/22 Unusually active option classes on open May 18th 04/26/22 Walgreen Boots call volume above normal and directionally bullish 04/22/22 Walgreen Boots put volume heavy and directionally bearish $505.29 / -11.83 (-2.29%)
07/05/22 UnitedHealth put volume heavy and directionally bearish 06/22/22 Unusually active option classes on open June 22nd 06/09/22 UnitedHealth put volume heavy and directionally bearish 03/14/22 UnitedHealth put volume heavy and directionally bearish $10.32 / +2.065 (+25.02%)
05/04/22 1Life Healthcare options imply 17.3% move in share price post-earnings 02/23/22 1Life Healthcare options imply 18.1% move in share price post-earnings 02/03/22 Early notable gainers among liquid option names on February 3rd 01/12/22 Unusually active option classes on open January 12th 06/02/22 CVS Health put volume heavy and directionally bearish 05/04/22 Unusually active option classes on open May 4th 05/02/22 Unusually active option classes on open May 2nd 04/26/22 CVS Health call volume above normal and directionally bullish 01/06/22 Centene put volume heavy and directionally bearish 06/03/22 Cigna call volume above normal and directionally bullish 05/06/22 Early notable gainers among liquid option names on May 6th
Conference/Events
Biopharma & Biotech…
Biopharma & Biotech Analyst Chen, Biotech Analyst Agrawal and Biopharma Analyst Kim, along with Felix Urman, Asst Professor at Icahn School of Medicine, discuss new and emerging treatments for Atopic Dermatitis and Psoriasis, including JNJ's Tremfya, ABBV's Skyrizi, PFE's Eucrisa, REGN's Dupixent, AMGN's Otezla, INCY's Opzelura and ROIV's Vtama on an Analyst/Industry conference call to be held on July 14 at 1 pm.
Show Hide Related Items >> <<
05/24/22 Dermavant Sciences announces FDA approval of VTAMA cream, 1% 05/16/22 Aruvant announces oral presentation on ARU-1801 05/02/22 Roivant Sciences announces collaborations in targeted protein degradation 07/01/22 Regeneron completes acquisition of Sanofi's stake in Libtayo 06/29/22 Regeneron's SBLA for Eylea accepted for FDA review 06/24/22 Regeneron, Intellia Therapeutics present data from Phase 1 study of NTLA-2001 06/24/22 Intellia, Regeneron present updated data from Phase 1 study of NTLA-2001 07/05/22 CureVac files patent infringement suit in Germany against BioNTech 06/30/22 Pfizer submits NDA to FDA for PAXLOVID 06/29/22 Pfizer/BioNTech enter new $3.2B deal with U.S. government on COVID vaccines 06/28/22 Pfizer and Roivant Sciences unveil Priovant Therapeutics 06/28/22 MeiraGTx announces data from the MGT009 Phase 1/2 clinical study 06/24/22 Janssen receives positive CHMP opinion for IMBRUVICA 06/16/22 FTC says to ramp up enforcement against illegal drug rebate schemes 06/10/22 Janssen presents updated data at EHA for teclistamab 06/14/22 Eli Lilly, Incyte announce FDA approval of Olumiant 06/13/22 Pfizer, MorphoSys, Incyte collaborate over Monjuvi/TTI-622 combination 05/20/22 Eli Lilly, Incyte: EMA's CHMP issues positive opinion for OLUMIANT 05/18/22 BriaCell adds additional clinical sites for Phase I/IIa study of Bria-IMT 06/06/22 Amgen announces FDA approved RIABNI 06/05/22 Amgen, Takeda announce new data from Phase 3 PARADIGM trial of Vectibix 05/31/22 Amgen reports data from Phase 2 OCEAN-DOSE clinical study 05/26/22 Amgen to present new data from oncology pipeline at ASCO 06/30/22 Genmab to submit FDA application for epcoritamab in B-cell lymphoma 06/27/22 AbbVie: CHMP recommends approval of Rinvoq in nr-axSpA in adults 06/21/22 AbbVie submits sNDA to FDA for atogepant 06/17/22 AbbVie: FDA approves SKYRIZI to treat Crohn's disease 06/22/22 Daiwa Johnson & Johnson initiated with an Outperform at Daiwa 05/27/22 Needham Needham upgrades Boston Scientific to Buy, sees stock as potential M&A target 05/23/22 SVB Securities Johnson & Johnson assumed with an Outperform at SVB Leerink 05/17/22 BofA Teva upgraded to Neutral at BofA on potential opioid deal upside 05/23/22 SVB Securities AbbVie initiated with an Underperform at SVB Leerink 05/13/22 Piper Sandler Atopic dermatitis market looks 'increasingly crowded,' says Piper Sandler 05/06/22 Daiwa AbbVie downgraded to Neutral from Outperform at Daiwa 05/03/22 Morgan Stanley Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure 07/01/22 RBC Capital Enanta price target raised to $67 from $64 at RBC Capital 06/29/22 Evercore ISI Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data 06/22/22 Piper Sandler Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler 06/13/22 Morgan Stanley Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley 06/24/22 Chardan Intellia durability data for NTLA-2001 'looking good so far,' says Chardan 06/06/22 Jefferies Regeneron initiated with an Underperform at Jefferies 06/02/22 Piper Sandler Regeneron selloff on Libtayo deal overdone, says Piper Sandler 05/31/22 Argus Regeneron price target raised to $760 from $680 at Argus 06/07/22 Stifel Mirati Therapeutics price target raised to $111 from $105 at Stifel 06/01/22 Oppenheimer Amgen price target raised to $290 from $285 at Oppenheimer 05/27/22 Stifel Mirati Therapeutics after-hours move lower 'overdone,' says Stifel 05/23/22 SVB Securities Radius Health initiated with a Market Perform at SVB Leerink 05/03/22 Stifel Incyte price target raised to $77 from $75 at Stifel 02/09/22 SVB Securities SVB Leerink downgrades Incyte to Underperform, lowers price target to $56 02/09/22 SVB Securities Incyte downgraded to Underperform from Market Perform at SVB Leerink 01/18/22 RBC Capital Incyte upgraded to Outperform at RBC Capital on improving 2022 setup 05/23/22 SVB Securities Roivant Sciences initiated with an Outperform at SVB Leerink 04/29/22 Cantor Fitzgerald Roivant Sciences initiated with an Overweight at Cantor Fitzgerald 12/15/21 Goldman Sachs Roivant Sciences initiated with a Buy at Goldman Sachs 12/02/21 H.C. Wainwright H.C. Wainwright says Arbutus patent win may mean 'considerable gain' for Roivant 06/28/22 Roivant Sciences reports Q4 EPS (39c), consensus (32c) 02/14/22 Roivant Sciences reports Q4 EPS (41c), consensus (25c) 05/04/22 Regeneron reports Q1 EPS $11.49, consensus $9.89 02/04/22 Regeneron reports Q4 EPS $23.72, consensus $18.02 02/03/22 Notable companies reporting before tomorrow's open 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open 04/19/22 Johnson & Johnson cuts FY22 adj. EPS view to $10.15-$10.35 from $10.40-$10.60 04/19/22 Johnson & Johnson reports Q1 adjusted EPS $2.67, consensus $2.61 04/18/22 Notable companies reporting before tomorrow's open 05/03/22 Incyte reaffirms prior FY22 guidance 05/03/22 Incyte reports Q1 EPS 55c, consensus 67c 02/08/22 Incyte reports Q4 EPS 10c, consensus 86c 04/27/22 Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.63 04/27/22 Amgen reports Q1 adjusted EPS $4.25, consensus $4.10 04/27/22 Notable companies reporting after market close 02/08/22 Amgen sees FY22 revenue $25.4B-$26.5B, consensus $27B 04/29/22 AbbVie sees FY22 revenue $59.4B, consensus $60.22B 04/29/22 AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50 04/29/22 AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20 04/29/22 AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14 01/25/22 White House limits use of Regeneron, Lilly Covid-19 antibody drugs, WSJ reports 06/23/22 Moderna vaccine for kids gets backing of CDC advisers, WSJ reports 06/12/22 Review says Pfizer vaccine works safely in young children, WSJ reports 06/02/22 Pfizer ask FDA to authorize three doses of vaccine for kids under 5, WSJ report 06/28/22 FDA panel recommends omicron update for COVID vaccine boosters, CNBC says 06/14/22 FTC asked to investigate price hikes by Janssen, Bristol-Myers, STAT says 06/07/22 J&J to end Covid-19 vaccine deal with Emergent BioSolutions, WSJ reports 06/06/22 CFOs send letter to Treasury Secretary on foreign tax credit rules, WSJ reports 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 05/10/22 Teva, Allergan offering over $5B to settle opioid suits, Bloomberg says 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports 06/28/22 Fly Intel: Pre-market Movers 05/24/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street On Tuesday 04/19/22 What You Missed On Wall Street This Morning 04/19/22 Street expert sees over 800% upside for this potential biotech M&A target 06/30/22 What You Missed On Wall Street On Thursday 06/30/22 What You Missed On Wall Street This Morning 06/30/22 Fly Intel: Pre-market Movers 06/29/22 What You Missed On Wall Street On Wednesday 06/29/22 What You Missed On Wall Street This Morning 06/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/24/22 What You Missed On Wall Street This Morning 02/28/22 Fly Insider: Warby Parker, Asana among week's notable insider trades 02/09/22 Wall Street in Fives - Must Read Lists for Wednesday 02/09/22 Wall Street in Fives - Must Read Lists at Midday 02/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/28/22 What You Missed On Wall Street On Thursday 04/27/22 Fly Intel: After-Hours Movers 02/08/22 Wall Street in Fives - Must Read Lists for Tuesday 05/23/22 What You Missed On Wall Street On Monday 05/23/22 What You Missed On Wall Street This Morning 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/10/22 What You Missed On Wall Street On Tuesday 01/11/22 Nine new option listings on January 11th 06/30/22 Early notable gainers among liquid option names on June 30th 05/20/22 Early notable gainers among liquid option names on May 20th 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th 06/28/22 Johnson & Johnson put volume heavy and directionally bearish 05/31/22 Johnson & Johnson put volume heavy and directionally bearish 04/19/22 Unusually active option classes on open April 19th 01/25/22 Unusually active option classes on open January 25th 06/27/22 Amgen put volume heavy and directionally bearish 02/08/22 Early notable gainers among liquid option names on February 8th 04/29/22 Unusually active option classes on open April 29th 02/24/22 AbbVie put volume heavy and directionally bearish 01/24/22 AbbVie put volume heavy and directionally bearish
Conference/Events
Pharmaceuticals Analysts…
Pharmaceuticals Analysts discuss new and emerging treatments for breast cancer and the debate surrounding Pfizer/Arvinas's ARV-471 Analyst/Industry conference call to be held on July 14 at 11 am.
Show Hide Related Items >> <<
07/05/22 CureVac files patent infringement suit in Germany against BioNTech 06/30/22 Pfizer submits NDA to FDA for PAXLOVID 06/29/22 Pfizer/BioNTech enter new $3.2B deal with U.S. government on COVID vaccines 06/28/22 Pfizer and Roivant Sciences unveil Priovant Therapeutics 05/09/22 Arvinas, GNS Healthcare announce neuroscience drug discovery collaboration 05/05/22 Arvinas announces anticipated milestones and expectations 02/17/22 Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide 02/17/22 Arvinas announces Phase 1, interim Phase 2 data for bavdegalutamide 07/01/22 RBC Capital Enanta price target raised to $67 from $64 at RBC Capital 06/29/22 Evercore ISI Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data 06/22/22 Piper Sandler Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler 06/13/22 Morgan Stanley Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley 05/23/22 Piper Sandler Arvinas price target lowered to $76 from $116 at Piper Sandler 05/09/22 Wedbush Wedbush downgrades Arvinas to Neutral, cuts price target to $43 05/09/22 Wedbush Arvinas downgraded to Neutral from Outperform at Wedbush 05/06/22 Cantor Fitzgerald Arvinas assumed with an Overweight at Cantor Fitzgerald 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open 05/05/22 Arvinas reports Q1 EPS ($1.20), consensus (89c) 02/28/22 Arvinas reports Q4 EPS ($1.00), consensus (79c) 06/28/22 FDA panel recommends omicron update for COVID vaccine boosters, CNBC says 06/23/22 Moderna vaccine for kids gets backing of CDC advisers, WSJ reports 06/12/22 Review says Pfizer vaccine works safely in young children, WSJ reports 06/02/22 Pfizer ask FDA to authorize three doses of vaccine for kids under 5, WSJ report 06/30/22 What You Missed On Wall Street On Thursday 06/30/22 What You Missed On Wall Street This Morning 06/30/22 Fly Intel: Pre-market Movers 06/29/22 What You Missed On Wall Street On Wednesday 05/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/30/22 Early notable gainers among liquid option names on June 30th 05/20/22 Early notable gainers among liquid option names on May 20th 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th
Hot Stocks
CureVac N.V. (CVAC)…
CureVac N.V. (CVAC) announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development. CureVac has filed a lawsuit in the German Regional Court in Dusseldorf against BioNTech (BNTX) and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac's intellectual property rights, EP 1 857 122 B1, DE 20 2015 009 961 U1, DE 20 2021 003 575 U1 and DE 20 2015 009 974 U1, utilized in the manufacture and sale of Comirnaty, BioNTech and Pfizer's (PFE) mRNA COVID-19 vaccine. CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale or distribution of Comirnaty by BioNTech and its partner Pfizer. The company said, "The CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTech's SARS CoV-2 mRNA vaccine, among others. These relate to the engineering of mRNA molecules, including sequence modifications to increase stability and enhance protein expression, as well as mRNA vaccine formulations specific to SARS CoV-2 vaccines. Over the last 22 years, CureVac developed proprietary foundational technology related to mRNA design, delivery and manufacturing that materially contributed to the development of safe and efficacious COVID-19 vaccines. CureVac considers the rapid development of these vaccines a tremendous achievement, with unprecedented positive impact for global public health. This achievement is based on decades of scientific research and innovation, supported by CureVac as the earliest pioneer in mRNA technology. Accordingly, CureVac's intellectual property rights need to be acknowledged and respected in the form of a fair compensation to reinvest into the further advancement of mRNA technology and the ongoing development of new classes of life saving medicines."
Show Hide Related Items >> <<
06/30/22 Pfizer submits NDA to FDA for PAXLOVID 06/28/22 Pfizer and Roivant Sciences unveil Priovant Therapeutics 06/27/22 Medtronic names Pfizer executive Lidia Fonseca as new director 05/25/22 CureVac partners with myNEO to identify novel antigen targets 05/25/22 CureVac enters research and option agreement with myNEO 04/21/22 CureVac announces second-generation COVID-19 vaccine candiate results 04/21/22 CureVac, GSK announces preclinical data on second-generation COVID vaccine $157.48 / +8.545 (+5.74%)
06/29/22 Pfizer/BioNTech enter new $3.2B deal with U.S. government on COVID vaccines 06/25/22 Pfizer, BioNTech announce data evaluating omicron-adapted vaccine candidates 06/23/22 BioNTech receives PRIME designation for BNT211 in testicular cancer 06/23/22 BioNTech starts construction on first mRNA vaccine facility in Africa 01/21/22 BofA CureVac cut to Underperform at BofA on limited catalyst flow this year 01/21/22 BofA CureVac downgraded to Underperform from Neutral at BofA 01/18/22 JMP Securities CureVac initiated with an Outperform at JMP Securities 12/22/21 Kempen CureVac downgraded to Sell from Neutral at Kempen $157.48 / +8.545 (+5.74%)
06/13/22 Morgan Stanley Moderna pediatric EUA vaccine briefing docs 'clean,' says Morgan Stanley 04/12/22 H.C. Wainwright BioNTech price target lowered to $298 from $339 at H.C. Wainwright 04/11/22 H.C. Wainwright H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab 04/05/22 Canaccord BioNTech price target lowered to $300 from $450 at Canaccord 07/01/22 RBC Capital Enanta price target raised to $67 from $64 at RBC Capital 06/29/22 Evercore ISI Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data 06/22/22 Piper Sandler Enanta's lawsuit against Pfizer 'not surprising,' says Piper Sandler 05/03/22 Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55 05/03/22 Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47 05/02/22 Notable companies reporting before tomorrow's open 05/25/22 CureVac reports Q1 revenue EUR 24.4M vs. EUR 10M last year 04/28/22 CureVac reports Q4 revenue EUR 41.2M vs. EUR 6M last year $157.48 / +8.545 (+5.74%)
05/09/22 BioNTech reports Q1 EPS EUR 14.24 vs. EUR 4.39 last year 03/30/22 BioNTech reports Q4 EPS EUR 12.18 vs. EUR 1.43 last year $157.48 / +8.545 (+5.74%)
06/28/22 FDA panel recommends omicron update for COVID vaccine boosters, CNBC says 06/23/22 Moderna vaccine for kids gets backing of CDC advisers, WSJ reports 06/12/22 Review says Pfizer vaccine works safely in young children, WSJ reports 06/02/22 Pfizer ask FDA to authorize three doses of vaccine for kids under 5, WSJ report 01/21/22 Wall Street in Fives - Must Read Lists for Friday 01/21/22 Wall Street in Fives - Must Read Lists at Midday 01/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations $157.48 / +8.545 (+5.74%)
06/30/22 What You Missed On Wall Street On Thursday 06/30/22 What You Missed On Wall Street This Morning 06/30/22 Fly Intel: Pre-market Movers 06/29/22 What You Missed On Wall Street On Wednesday 06/30/22 Early notable gainers among liquid option names on June 30th 05/20/22 Early notable gainers among liquid option names on May 20th 04/26/22 Unusually active option classes on open April 26th 04/11/22 Unusually active option classes on open April 11th $157.48 / +8.545 (+5.74%)
06/09/22 BioNTech SE put volume heavy and directionally bearish 06/06/22 BioNTech SE call volume above normal and directionally bullish 06/03/22 Notable open interest changes for June 3rd 03/30/22 Unusually active option classes on open March 30th
